A “double mutant” strain of the CCP virus believed to be behind a spike of cases in India has been discovered in California’s Bay Area, officials confirmed Sunday.
Stanford is also screening seven further presumptive cases of the “double mutant” strain, which carries two mutations in the spike protein—L452R and E484—that may help the virus bind more readily to receptors in human cells.
It is unclear whether the emerging strain is more resistant to the three COVID-19 vaccines that have been authorized for emergency use in the United States so far—Pfizer/BioNTech, Moderna, and Johnson & Johnson.
“This Indian variant contains two mutations in the same virus for the first time, previously seen on separate variants,” Dr. Peter Chin-Hong, an infectious diseases expert at the University of California San Francisco, told the news outlet.
“Since we know that the domain affected is the part that the virus uses to enter the body, and that the California variant is already potentially more resistant to some vaccine antibodies, it seems to reason that there is a chance that the Indian variant may do that too,” Chin-Hong added.
“It also makes sense that it will be more transmissible from a biological perspective as the two mutations act at the receptor-binding domain of the virus, but there have been no official transmission studies to date.”
It polled 77 experts from top academic institutions from 28 countries, of which nearly a third of respondents said that they believe current vaccines could be rendered useless within nine months.